Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.
FiercePharma1d
Fierce Pharma Asia—Merck's collabs with Daiichi, Eisai deliver readouts; Granules hit with FDA manufacturing observations
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...
devdiscourse3d
Recent Health Developments: Affordable Medicines, Breakthrough Devices, and Global Campaigns
This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...
AstraZeneca Shares Set For Worst Week in 14 Months on Sell Calls
AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the ...
world-nuclear-news11d
Fuel debris removal attempt halted at Fukushima Daiichi
Tokyo Electric Power Company has suspended the first attempt to extract fuel debris from within the primary containment vessel of unit 2 at the damaged Fukushima ...
TipRanks on MSN11d
AstraZeneca Shares Fall on Lung Cancer Drug Trial’s Outcome
Shares of AstraZeneca PLC ($GB:AZN) fell by over 3% as of writing after the pharma company released an unsatisfactory outcome ...
Business Insider14d
Merck & Daiichi Sankyo's Ifinatamab Deruxtecan Shows Promising Results In Phase 2 Lung Cancer Trial
According to the companies, an objective response rate of 54.8% was observed with Daiichi Sankyo and Merck's ifinatamab deruxtecan at a 12 mg/kg dose in pretreated patients. This dose has been ...
Seeking Alpha14d
Merck, Daiichi post mid-stage data for novel lung cancer drug
Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSNKY) (OTCPK:DSKYF) on Saturday announced interim results from a Phase 2 trial for lung cancer patients treated with ifinatamab deruxtecan (I-DXd ...